Invention Grant
- Patent Title: Clostridium difficile toxin inhibitors
-
Application No.: US16308041Application Date: 2017-06-08
-
Publication No.: US10669242B2Publication Date: 2020-06-02
- Inventor: Jeffrey J. Letourneau , Andrew G. Cole , Brett A. Marinelli , Jorge G. Quintero
- Applicant: Venenum Biodesign, LLC
- Applicant Address: US NJ Hamilton
- Assignee: Venenum Biodesign, LLC
- Current Assignee: Venenum Biodesign, LLC
- Current Assignee Address: US NJ Hamilton
- Agent Arnold Braun; Terence Bogie
- International Application: PCT/US2017/036494 WO 20170608
- International Announcement: WO2017/214359 WO 20171214
- Main IPC: C07D401/06
- IPC: C07D401/06 ; C07D401/08 ; C07D401/10 ; C07D401/12 ; C07D401/14 ; C07D403/06 ; C07D403/08 ; C07D403/10 ; C07D403/12 ; C07D403/14 ; C07D413/04 ; C07D413/06 ; C07D413/08 ; C07D413/10 ; C07D413/12 ; C07D413/14 ; C07D417/04 ; C07D417/06 ; C07D417/08 ; C07D417/10 ; C07D417/12 ; C07D417/14 ; C07D243/32 ; C07D471/04 ; C07D243/14 ; C07D403/04 ; A61P31/04 ; C07D409/14

Abstract:
The present invention relates to benzodiazepine derivative compounds of formula (I), or pharmaceutically acceptable salts thereof. The present benzodiazepine compounds are useful Clostridium difficile inhibitors in the treatment of Clostridium difficile infection in humans. The present invention provides a pharmaceutical composition containing benzodiazepine compounds of formula (I) and a method of making as well as a method of using the same in treating patients infected with Clostridium difficile infection by administering the same. The compounds of the present invention may be used in combination with additional antibiotics or anti-toxin antibody drugs.
Public/Granted literature
- US20190194147A1 Novel Clostridium Difficile Toxin Inhibitors Public/Granted day:2019-06-27
Information query